Literature DB >> 33255759

An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier.

Mi-Kyoung Seo1, Soonmyung Paik2, Sangwoo Kim1.   

Abstract

While intrinsic molecular subtypes provide important biological classification of breast cancer, the subtype assignment of individuals is influenced by assay technology and study cohort composition. We sought to develop a platform-independent absolute single-sample subtype classifier based on a minimal number of genes. Pairwise ratios for subtype-specific differentially expressed genes from un-normalized expression data from 432 breast cancer (BC) samples of The Cancer Genome Atlas (TCGA) were used as inputs for machine learning. The subtype classifier with the fewest number of genes and maximal classification power was selected during cross-validation. The final model was evaluated on 5816 samples from 10 independent studies profiled with four different assay platforms. Upon cross-validation within the TCGA cohort, a random forest classifier (MiniABS) with 11 genes achieved the best accuracy of 88.2%. Applying MiniABS to five validation sets of RNA-seq and microarray data showed an average accuracy of 85.15% (vs. 77.72% for Absolute Intrinsic Molecular Subtype (AIMS)). Only MiniABS could be applied to five low-throughput datasets, showing an average accuracy of 87.93%. The MiniABS can absolutely subtype BC using the raw expression levels of only 11 genes, regardless of assay platform, with higher accuracy than existing methods.

Entities:  

Keywords:  breast cancer; classifier; machine learning; optimization; subtyping

Year:  2020        PMID: 33255759      PMCID: PMC7761033          DOI: 10.3390/cancers12123506

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  37 in total

1.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Authors:  F Cardoso; S Kyriakides; S Ohno; F Penault-Llorca; P Poortmans; I T Rubio; S Zackrisson; E Senkus
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

2.  West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Authors:  Oleg Gluz; Ulrike A Nitz; Matthias Christgen; Ronald E Kates; Steven Shak; Michael Clemens; Stefan Kraemer; Bahriye Aktas; Sherko Kuemmel; Toralf Reimer; Manfred Kusche; Volker Heyl; Fatemeh Lorenz-Salehi; Marianne Just; Daniel Hofmann; Tom Degenhardt; Cornelia Liedtke; Christer Svedman; Rachel Wuerstlein; Hans H Kreipe; Nadia Harbeck
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

3.  Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathy S Albain; Thomas J Saphner; Sunil S Badve; Lynne I Wagner; Virginia G Kaklamani; Maccon M Keane; Henry L Gomez; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Deborah L Toppmeyer; Adam M Brufsky; Matthew P Goetz; Jeffrey L Berenberg; Catalin Mahalcioiu; Christine Desbiens; Daniel F Hayes; Elizabeth C Dees; Charles E Geyer; John A Olson; William C Wood; Tracy Lively; Soonmyung Paik; Matthew J Ellis; Jeffrey Abrams; George W Sledge
Journal:  JAMA Oncol       Date:  2020-03-01       Impact factor: 31.777

4.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors:  G Curigliano; H J Burstein; E P Winer; M Gnant; P Dubsky; S Loibl; M Colleoni; M M Regan; M Piccart-Gebhart; H-J Senn; B Thürlimann; F André; J Baselga; J Bergh; H Bonnefoi; S Y Brucker; F Cardoso; L Carey; E Ciruelos; J Cuzick; C Denkert; A Di Leo; B Ejlertsen; P Francis; V Galimberti; J Garber; B Gulluoglu; P Goodwin; N Harbeck; D F Hayes; C-S Huang; J Huober; K Hussein; J Jassem; Z Jiang; P Karlsson; M Morrow; R Orecchia; K C Osborne; O Pagani; A H Partridge; K Pritchard; J Ro; E J T Rutgers; F Sedlmayer; V Semiglazov; Z Shao; I Smith; M Toi; A Tutt; G Viale; T Watanabe; T J Whelan; B Xu
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

5.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

Authors:  Christos Hatzis; Lajos Pusztai; Vicente Valero; Daniel J Booser; Laura Esserman; Ana Lluch; Tatiana Vidaurre; Frankie Holmes; Eduardo Souchon; Hongkun Wang; Miguel Martin; José Cotrina; Henry Gomez; Rebekah Hubbard; J Ignacio Chacón; Jaime Ferrer-Lozano; Richard Dyer; Meredith Buxton; Yun Gong; Yun Wu; Nuhad Ibrahim; Eleni Andreopoulou; Naoto T Ueno; Kelly Hunt; Wei Yang; Arlene Nazario; Angela DeMichele; Joyce O'Shaughnessy; Gabriel N Hortobagyi; W Fraser Symmans
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

6.  Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer.

Authors:  Deena M A Gendoo; Natchar Ratanasirigulchai; Markus S Schröder; Laia Paré; Joel S Parker; Aleix Prat; Benjamin Haibe-Kains
Journal:  Bioinformatics       Date:  2015-11-24       Impact factor: 6.937

7.  The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine.

Authors:  Lao H Saal; Johan Vallon-Christersson; Jari Häkkinen; Cecilia Hegardt; Dorthe Grabau; Christof Winter; Christian Brueffer; Man-Hung Eric Tang; Christel Reuterswärd; Ralph Schulz; Anna Karlsson; Anna Ehinger; Janne Malina; Jonas Manjer; Martin Malmberg; Christer Larsson; Lisa Rydén; Niklas Loman; Åke Borg
Journal:  Genome Med       Date:  2015-02-02       Impact factor: 11.117

8.  Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

Authors:  John M S Bartlett; Jane Bayani; Andrea Marshall; Janet A Dunn; Amy Campbell; Carrie Cunningham; Monika S Sobol; Peter S Hall; Christopher J Poole; David A Cameron; Helena M Earl; Daniel W Rea; Iain R Macpherson; Peter Canney; Adele Francis; Christopher McCabe; Sarah E Pinder; Luke Hughes-Davies; Andreas Makris; Robert C Stein
Journal:  J Natl Cancer Inst       Date:  2016-04-29       Impact factor: 13.506

9.  PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

Authors:  Roy R L Bastien; Álvaro Rodríguez-Lescure; Mark T W Ebbert; Aleix Prat; Blanca Munárriz; Leslie Rowe; Patricia Miller; Manuel Ruiz-Borrego; Daniel Anderson; Bradley Lyons; Isabel Álvarez; Tracy Dowell; David Wall; Miguel Ángel Seguí; Lee Barley; Kenneth M Boucher; Emilio Alba; Lisa Pappas; Carole A Davis; Ignacio Aranda; Christiane Fauron; Inge J Stijleman; José Palacios; Antonio Antón; Eva Carrasco; Rosalía Caballero; Matthew J Ellis; Torsten O Nielsen; Charles M Perou; Mark Astill; Philip S Bernard; Miguel Martín
Journal:  BMC Med Genomics       Date:  2012-10-04       Impact factor: 3.063

10.  Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

Authors:  A Prat; A Lluch; J Albanell; W T Barry; C Fan; J I Chacón; J S Parker; L Calvo; A Plazaola; A Arcusa; M A Seguí-Palmer; O Burgues; N Ribelles; A Rodriguez-Lescure; A Guerrero; M Ruiz-Borrego; B Munarriz; J A López; B Adamo; M C U Cheang; Y Li; Z Hu; M L Gulley; M J Vidal; B N Pitcher; M C Liu; M L Citron; M J Ellis; E Mardis; T Vickery; C A Hudis; E P Winer; L A Carey; R Caballero; E Carrasco; M Martín; C M Perou; E Alba
Journal:  Br J Cancer       Date:  2014-08-07       Impact factor: 7.640

View more
  1 in total

1.  Tumor microenvironment-aware, single-transcriptome prediction of microsatellite instability in colorectal cancer using meta-analysis.

Authors:  Mi-Kyoung Seo; Hyundeok Kang; Sangwoo Kim
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.